实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (2): 164-171.doi: 10.3969/j.issn.1672-5069.2019.02.004
中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组
出版日期:2019-03-10
发布日期:2019-03-19
作者简介:李兰娟,浙江大学医学院附属第一医院传染病诊治国家重点实验室,杭州310003,E-mail：ljli@zju.edu.cn;韩涛,天津市第三中心医院肝病内科,300170,E-mail：hantaomd@126.com
Guideline for diagnosis, treatment of liver failure
Online:2019-03-10
Published:2019-03-19
Contact:
Corresponding author:Li Lanjuan,Email：ljli@zju.edu.cn,State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;
中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南（2018年版）[J]. 实用肝脏病杂志, 2019, 22(2): 164-171.
Guideline for diagnosis, treatment of liver failure. [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 164-171.
| [1] Polson J,Lee WM.AASLD position paper:the management of acute liver failure[J]. Hepatology,2005,41(5):1179-1197. DOI: 10.1002/hep.20703. [2] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊疗指南[J]. 中华肝脏病杂志,2006,14(9):643-646. Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association. Diagnostic and treatment guidelines for liver failure[J].Chin J Hepatol,2006,14(9):643-646. (in Chinese) [3] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华临床感染病杂志,2012,5(6):321-327. DOI:10.3969/j.issn.1672-5069.2013.03.007. Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,CMA;Severe Liver Disease and Artificial Liver Group,Chinese Society of Hepatology,CMA. Guideline for diagnosis and treatment of liver failure[J]. Chin J Clin Infect Dis,2012,5(6):321-327. DOI10.3969/j.issn.1672-5069.2013.03.007.(in Chinese) [4] Sarin SK,Kedarisetty CK,Abbas Z,et al.Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL) 2014[J]. Hepatol Int,2014,8(4):453-471. DOI: 10.1007/s12072-014-9580-2. [5] European Association for the Study of the Liver. EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J]. J Hepatol,2017,66(5):1047-1081. DOI: 10.1016/j.jhep.2016.12.003. [6] Flamm SL,Yang YX,Singh S,et al.American gastroenterological association institute guidelines for the diagnosis and management of acute liver failure[J]. Gastroenterology,2017,152(3):644-647. DOI:10.1053/j.gastro.2016.12.026. [7] Wu T,Li J,Shao L,et al.Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut,2018,67(12):2181-2191. DOI:10.1136/ gutjnl-2017-314641. [8] Jalan R,Yurdaydin C,Bajaj JS,et al.Toward an improved definition of acute-on-chronic liver failure[J]. Gastroenterology,2014,147(1):4-10. DOI:10.1053/j.gastro.2014.05.005. [9] Zhang Q,Li Y,Han T,et al.Comparison of current diagnostic criteria for acute-on-chronic liver failure[J/OL]. PLoS One,2015,10(3):e0122158. DOI:10.1371/journal.pone.0122158. [10] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J]. J Hepatol,2018,pii:S0168-8278(18):32177-32179. DOI:10.1016/ j.jhep.2018.06.024. [11] Chen Y,Yang F,Lu H,et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J]. Hepatology,2011,54(2):562-572. DOI:10.1002/hep.24423. [12] Tilg H,Cani PD,Mayer EA.Gut microbiome and liver diseases[J]. Gut,2016,65(12):2035-2044. DOI:10.1136/gutjnl-2016- 312729. [13] Petrof EO,Khoruts A. From stool transplants to next-generation microbiota therapeutics[J]. Gastroenterology,2014,146(6):1573- 1582. DOI: 10.1053/j.gastro.2014.01.004. [14] Rockey DC,Seeff LB,Rochon J,et al.Causality assessment in drug-induced liver injury using a structured expert opinion process:comparison to the Roussel-Uclaf causality assessment method[J]. Hepatology,2010,51(6):2117-2126. DOI: 10.1002/ hep.23577. [15] Jindal A,Kumar M,Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B[J]. Liver Int,2013,33 Suppl 1:164-175. DOI:10.1111/liv.12081. [16] Sun LJ,Yu JW,Zhao YH,et al.Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure[J]. J Gastroenterol Hepatol,2010,25(3):583-590. DOI:10.1111/j.1440-1746.2009.06089.x. [17] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol,2018,69(2):461-511. DOI:10.1016/j.jhep.2018.03.026. [18] Smilkstein MJ,Knapp GL,Kulig KW,et al.Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985)[J]. N Engl J Med,1988,319(24):1557-1562. DOI: 10.1056/NEJM198812153192401. [19] Keays R,Harrison PM,Wendon JA,et al.Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure:a prospective controlled trial[J]. BMJ,1991,303(6809):1026-1029. DOI:10.1136/bmj.303.6809.1026. [20] Lee WM,Hynan LS,Rossaro L,et al.Intravenous N-acetylcysteine improves transplant-free survival in early stage non- acetaminophen acute liver failure[J]. Gastroenterology,2009,137(3):856-864. DOI:10.1053/j.gastro.2009.06.006. [21] Hruby K,Csomos G,Fuhrmann M,et al.Chemotherapy of amanita phalloides poisoning with intravenous silibinin[J]. Hum Toxicol,1983,2(2):183-195. [22] Broussard CN,Aggarwal A,Lacey SR,et al.Mushroom poisoning-from diarrhea to liver transplantation[J]. Am J Gastroenterol,2001,96(11):3195-3198. DOI:10.1111/j.1572-0241.2001.05283.x. [23] Enjalbert F,Rapior S,Nouguier-Soulé J,et al.Treatment of amatoxin poisoning:20-year retrospective analysis[J]. J Toxicol Clin Toxicol,2002,40(6):715-757. DOI:10.1081/CLT-120014646. [24] Canalese J,Gimson AE,Davis C,et al.Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure[J]. Gut,1982,23(7):625-629. DOI:10.1136/gut.23.7.625. [25] Klinck J,McNeill L,Di Angelantonio E,et al. Predictors and outcome impact of perioperative serum sodium changes in a high-risk population[J]. Br J Anaesth,2015,114(4):615-622. DOI:10.1093/bja/aeu409. [26] Jalan R,Olde Damink SW,Deutz NE,et al.Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia[J]. Hepatology,2001,34(1):50-54. DOI:10.1053/jhep.2001.25386. [27] Jalan R,O Damink SW,Deutz NE,et al. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure[J]. Lancet,1999,354(9185):1164-1168. DOI:10.1016/S0140 -6736(98)12440-6. [28] Tofteng F,Larsen FS.The effect of indomethacin on intracranial pressure,cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure[J]. J Cereb Blood Flow Metab,2004, 24(7):798-804. DOI10.1097/01.WCB.0000125648.03213.1D. [29] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南[J]. 中华内科杂志,2018,57(10):705-718. DOI:10.3760/cma.j.issn.0578-1426. 2018.10.004.Chinese Society of Hepatology,Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. Chin J Intern Med,2018,57(10):705-718. DOI:10.3760/cma.j.issn.0578-1426.2018.10.004.(in Chinese) [30] Vilstrup H,Amodio P,Bajaj J,et al.Hepatic encephalopathy in chronic liver disease:2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver[J]. Hepatology,2014,60(2):715-735. DOI:10.1002/hep.27210. [31] Gluud LL,Vilstrup H,Morgan MY.Nonabsorbable disaccharides for hepatic encephalopathy:A systematic review and meta-analysis[J]. Hepatology,2016,64(3):908-922. DOI: 10.1002/hep.28598. [32] Gluud LL,Vilstrup H,Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis[J]. Cochrane Database Syst Rev,2016(5):p. CD003044. DOI:10.1002/14651858.CD003044.pub4. [33] Bai M,Yang Z,Qi X,et al.L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis:a meta-analysis of randomized controlled trials[J]. J Gastroenterol Hepatol,2013,28(5):783-792. DOI:10.1111/jgh.12142. [34] Gluud LL,Dam G,Les I,et al. Branched-chain amino acids for people with hepatic encephalopathy[J]. Cochrane Database Syst Rev,2017,5:CD001939. DOI:10.1002/14651858.CD001939.pub4. [35] Laccetti M,Manes G,Uomo G,et al.Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients:a double blind randomized placebo controlled study[J]. Dig Liver Dis,2000,32(4):335-338. [36] Hanish SI,Stein DM,Scalea JR,et al.Molecular adsorbent recirculating system effectively replaces hepatic function in severe acute liver failure[J]. Ann Surg,2017,266(4):677-684. DOI: 10.1097/SLA.0000000000002361. [37] Saliba F,Camus C,Durand F,et al.Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized,controlled trial[J]. Ann Intern Med,2013,159(8):522-531. DOI: 10.7326/0003-4819-159-8-2013 10150-00005. [38] Rolando N,Philpott-Howard J,Williams R.Bacterial and fungal infection in acute liver failure[J]. Semin Liver Dis,1996,16(4):389-402. DOI:10.1055/s-2007-1007252. [39] Silvestre JP,Coelho LM,Póvoa PM.Impact of fulminant hepatic failure in C-reactive protein[J]. J Crit Care,2010,25(4):657. e7-12. DOI:10.1016/j.jcrc.2010.02.004. [40] Rule JA,Hynan LS,Attar N,et al.Procalcitonin identifies cell injury,not bacterial infection,in acute liver failure[J/OL]. PLoS One,2015,10(9):e0138566. DOI:10.1371/journal.pone.0138566. [41] Karvellas CJ,Cavazos J,Battenhouse H,et al. Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure:a retrospective cohort study[J]. Clin Gastroenterol Hepatol,2014,12(11):1942-1949. e1. DOI:10.1016/j.cgh.2014.03.011. [42] Bernal W,Auzinger G,Dhawan A,et al.Acute liver failure[J]. Lancet,2010,376(9736):190-201. DOI:10.1016/S0140-6736(10)60274-7. [43] Farmakiotis D,Kontoyiannis DP.Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipients[J]. Am J Transplant,2015,15(5):1141-1147. DOI: 10.1111/ajt.13186. [44] Uojima H,Kinbara T,Hidaka H,et al.Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites[J]. Hepatol Res,2017,47(3):E14-E21. DOI:10.1111/hepr.12716. [45] Yan L,Xie F,Lu J,et al.The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites:a meta-analysis of randomized controlled trials[J]. BMC Gastroenterol,2015,15:65. DOI:10.1186/s12876-015-0297-z. [46] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol,2018,69(2):406-460. DOI: 10.1016/j.jhep.2018.03.024. [47] Mindikoglu AL,Pappas SC. New developments in hepatorenal syndrome[J]. Clin Gastroenterol Hepatol,2018,16(2):162-177. e1. DOI:10.1016/j.cgh.2017.05.041. [48] Selby NM,Kubba AK,Hawkey CJ.Acid suppression in peptic ulcer haemorrhage:a 'meta-analysis'[J]. Aliment Pharmacol Ther,2000,14(9):1119-1126. [49] Leontiadis GI,Sharma VK,Howden CW.Proton pump inhibitor therapy for peptic ulcer bleeding:Cochrane collaboration meta-analysis of randomized controlled trials[J]. Mayo Clin Proc,2007,82(3):286-296. DOI:10.4065/82.3.286. [50] Ioannou G,Doust J,Rockey DC. Terlipressin for acute esophageal variceal hemorrhage[J]. Cochrane Database Syst Rev,2003,(1):CD002147. DOI:10.1002/14651858.CD002147. [51] Imperiale TF,Teran JC,McCullough AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage[J]. Gastroenterology,1995,109(4):1289-1294. [52] Laine L,Cook D.Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis[J]. Ann Intern Med,1995,123(4):280-287. [53] Lin LL,Du SM,Fu Y,et al.Combination therapy versus pharmacotherapy,endoscopic variceal ligation,or the transjugular intrahepatic portosystemic shunt alone in the secondary prevention of esophageal variceal bleeding:a meta-analysis of randomized controlled trials[J]. Oncotarget,2017,8(34):57399-57408. DOI: 10.18632/oncotarget.18143. [54] Pereira SP,Rowbotham D,Fitt S,et al.Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease[J]. J Hepatol,2005,42(3):365-370. DOI:10.1016/j.jhep.2004.11.030. [55] 中华医学会感染病学分会肝衰竭与人工肝学组. 非生物型人工肝治疗肝衰竭指南(2016年版)[J]. 中华临床感染病杂志,2016,9(2):97-103. DOI:10.3760/cma.j.issn.1674-2397.2016.02.001. Liver Failure and Artificial Liver Group,Branch of Infectious Diseases,Chinese Medical Association. Guideline for non-bioartificial liver support systems in treatment of liver failure:2016 update[J]. Chin J Clin Infect Dis,2016,9(2):97-103. DOI10.3760/cma.j.issn.1674-2397.2016.02.001.(in Chinese) [56] Steadman RH,Van Rensburg A,Kramer DJ.Transplantation for acute liver failure:perioperative management[J]. Curr Opin Organ Transplant,2010,15(3):368-373. DOI:10.1097/MOT.0b013e32 833982dd. [57] Ling Q,Xu X,Wei Q,et al.Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure[J/OL]. PLoS One,2012,7(1):e30322. DOI: 10.1371/journal.pone.0030322. [58] Mochida S. Indication criteria for liver transplantation for acute liver failure in Japan[J]. Hepatol Res,2008,38 Suppl 1:S52-55. DOI:10.1111/j.1872-034X.2008.00427.x. [59] 饶慧瑛,郭芳,魏来. 2005年美国肝病学会急性肝衰竭诊治和肝移植患者评价指南简介[J].中华肝脏病杂志,2006,14(2):154-156. DOI:10.3760/j.issn:1007-3418.2006.02.025. Rao HY, Guo F,Wei L. Introduction and comments on AASLD practice guidelines:diagnosis and treatment of acute liver failure and assessment of liver transplant patients[J].Chin J Hepatol,2006,14(2):154-156. DOI10.3760/j.issn:1007-3418.2006.02.025. (in Chinese) [60] Arroyo V,Moreau R,Kamath PS,et al.Acute-on-chronic liver failure in cirrhosis[J]. Nat Rev Dis Primers,2016,2:16041. DOI: 0.1038/nrdp.2016.41. [61] Linecker M,Krones T,Berg T,et al. Potentially inappropriate liver transplantation in the era of the “sickest first” policy-A search for the upper limits[J]. J Hepatol,2017,pii:S0168-8278(17)32430-3. DOI:0.1016/j.jhep.2017.11.008. |
| [1] | 庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767. |
| [2] | 鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769. |
| [3] | 中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792. |
| [4] | . 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803. |
| [5] | 任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807. |
| [6] | 徐飞, 李伟荣. 黄芪甲苷对CCL4所致肝损伤大鼠的保护作用*[J]. 实用肝脏病杂志, 2019, 22(6): 808-811. |
| [7] | 高磊, 曹蕾, 王瑞芳, 冯丹丹, 薛娟. 人脐带间充质干细胞移植对酒精性肝损伤大鼠的保护作用*[J]. 实用肝脏病杂志, 2019, 22(6): 812-815. |
| [8] | 朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819. |
| [9] | 石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823. |
| [10] | 闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827. |
| [11] | 张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831. |
| [12] | 吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835. |
| [13] | 马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839. |
| [14] | 潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843. |
| [15] | 汪道伟, 方坚, 范凌. 自身免疫性肝炎患者血清IL-21和趋化因子水平变化及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(6): 844-847. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
